Lønning P E, Helle S I, Johannessen D C, Adlercreutz H, Lien E A, Tally M, Ekse D, Fotsis T, Anker G B, Hall K
Department of Oncology, Haukeland University Hospital, Bergen, Norway.
Clin Endocrinol (Oxf). 1995 Jan;42(1):23-30. doi: 10.1111/j.1365-2265.1995.tb02594.x.
Oestrogens, androgens and anti-endocrine drugs such as tamoxifen and aminoglutethimide influence plasma insulin-like growth factor-I (IGF-I). IGF-I, in turn, has been found to stimulate the peripheral aromatase in vitro. The aim of this study was to examine relations between sex hormones, IGF-I and insulin-like growth factor binding protein-1 (IGFBP-1) in post-menopausal women with breast cancer.
To measure plasma sex steroids, sex hormone binding globulin (SHBG), IGF-I, IGFBP-1, insulin and urinary oestrogen metabolites in post-menopausal women with breast cancer not receiving any endocrine therapy.
Thirty-two patients had fasting blood samples obtained between 0800 and 1000 h. A sub-group of 10 patients had 24-hour urine oestrogen metabolites determined.
Plasma steroids and proteins were measured by radioimmunoassays. Urinary oestrogens were measured by GC-MS.
SHBG correlated negatively with plasma androstenedione (P < 0.001), insulin (P < 0.001), IGF-I, height and plasma oestrone sulphate (P < 0.025 for all), but positively with plasma IGFBP-1 (P < 0.025). IGFBP-1 correlated negatively with IGF-I (P < 0.001) and the testosterone/SHBG ratio (P < 0.05). Neither IGF-I nor IGFBP-1 correlated with any of the plasma or urinary sex hormones or with the oestrone/androstenedione and oestradiol/testosterone ratios. Multivariate analysis revealed plasma SHBG to correlate positively with IGFBP-1 (P = 0.029) and negatively with insulin (P = 0.031). Plasma IGFBP-1 correlated negatively with IGF-I (P < 0.0001) but not with insulin.
Our results do not suggest any influence of plasma sex steroids in physiological concentrations on IGF-I or IGFBP-1 in post-menopausal breast cancer patients, nor do they indicate IGF-I at physiological concentrations influences the ratios between plasma oestrogens and their androgen precursors.
雌激素、雄激素以及他莫昔芬和氨鲁米特等抗内分泌药物会影响血浆胰岛素样生长因子-I（IGF-I）。反过来，已发现IGF-I在体外可刺激外周芳香化酶。本研究的目的是检测绝经后乳腺癌女性体内性激素、IGF-I和胰岛素样生长因子结合蛋白-1（IGFBP-1）之间的关系。
测量未接受任何内分泌治疗的绝经后乳腺癌女性的血浆性激素、性激素结合球蛋白（SHBG）、IGF-I、IGFBP-1、胰岛素以及尿雌激素代谢物。
32例患者于08:00至10:00采集空腹血样。10例患者的亚组测定了24小时尿雌激素代谢物。
血浆类固醇和蛋白质通过放射免疫分析法测定。尿雌激素通过气相色谱-质谱联用仪测定。
SHBG与血浆雄烯二酮（P < 0.001）、胰岛素（P < 0.001）、IGF-I、身高以及血浆硫酸雌酮（均P < 0.025）呈负相关，但与血浆IGFBP-1呈正相关（P < 0.025）。IGFBP-1与IGF-I（P < 0.001）以及睾酮/SHBG比值（P < 0.05）呈负相关。IGF-I和IGFBP-1均与任何血浆或尿性激素以及雌酮/雄烯二酮和雌二醇/睾酮比值均无相关性。多变量分析显示血浆SHBG与IGFBP-1呈正相关（P = 0.029），与胰岛素呈负相关（P = 0.031）。血浆IGFBP-1与IGF-I呈负相关（P < 0.0001），但与胰岛素无相关性。
我们的结果表明，生理浓度的血浆性激素对绝经后乳腺癌患者的IGF-I或IGFBP-1没有任何影响，也未表明生理浓度的IGF-I会影响血浆雌激素与其雄激素前体之间的比值。
